[HTML][HTML] Glucagon-like peptide 1 (GLP-1)
TD Müller, B Finan, SR Bloom, D D'Alessio… - Molecular …, 2019 - Elsevier
Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …
Incretin hormones: Their role in health and disease
MA Nauck, JJ Meier - Diabetes, Obesity and Metabolism, 2018 - Wiley Online Library
Incretin hormones are gut peptides that are secreted after nutrient intake and stimulate
insulin secretion together with hyperglycaemia. GIP (glucose‐dependent insulinotropic …
insulin secretion together with hyperglycaemia. GIP (glucose‐dependent insulinotropic …
Biology of incretins: GLP-1 and GIP
This review focuses on the mechanisms regulating the synthesis, secretion, biological
actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic …
actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic …
The physiology of glucagon-like peptide 1
JJ Holst - Physiological reviews, 2007 - journals.physiology.org
Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the
intestinal epithelial endocrine L-cells by differential processing of proglucagon, the gene …
intestinal epithelial endocrine L-cells by differential processing of proglucagon, the gene …
Pharmacology, physiology, and mechanisms of incretin hormone action
Incretin peptides, principally GLP-1 and GIP, regulate islet hormone secretion, glucose
concentrations, lipid metabolism, gut motility, appetite and body weight, and immune …
concentrations, lipid metabolism, gut motility, appetite and body weight, and immune …
Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
An absolute, supraphysiologic elevation in GFR is observed early in the natural history in
10%–67% and 6%–73% of patients with type 1 and type 2 diabetes, respectively. Moreover …
10%–67% and 6%–73% of patients with type 1 and type 2 diabetes, respectively. Moreover …
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
JJ Meier - Nature Reviews Endocrinology, 2012 - nature.com
In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised …
KR Tuttle, MC Lakshmanan, B Rayner… - The lancet Diabetes & …, 2018 - thelancet.com
Background Many antihyperglycaemic drugs, including insulin, are primarily cleared by the
kidneys, restricting treatment options for patients with kidney disease. Dulaglutide is a long …
kidneys, restricting treatment options for patients with kidney disease. Dulaglutide is a long …
[HTML][HTML] GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Type 2 diabetes mellitus (T2DM) is closely associated with cardiovascular diseases (CVD),
including atherosclerosis, hypertension and heart failure. Some anti-diabetic medications …
including atherosclerosis, hypertension and heart failure. Some anti-diabetic medications …